klonopin 2 mg clonazepam buy best bottle 100
klonopin 2 mg clonazepam
klonopin 2 mg clonazepam a benzodiazepine, is available as scored tablets with a K-shaped perforation containing 0.5 mg of clonazepam and unscored tablets with a K-shaped perforation containing 1 mg or 2 mg of clonazepam. Each tablet also contains lactose, magnesium stearate, microcrystalline cellulose and corn starch, with the following colorants: 0.5 mg—FD&C Yellow No. 6 Lake; 1 mg—FD&C Blue No. 1 Lake and FD&C Blue No. 2 Lake.
imprint klonopin 2 mg
Pill with imprint K ROCHE 2 K KLONOPIN is White, Round and has been identified as Klonopin 2 mg. It is supplied by Roche Laboratories. Klonopin is used in the treatment of panic disorder; seizure prevention; epilepsy and belongs to the drug classes benzodiazepine anticonvulsants, benzodiazepines. There is positive evidence of human fetal risk during pregnancy. Klonopin 2 mg is classified as a Schedule 4 controlled substance under the Controlled Substance Act (CSA). Labeler / Supplier: Roche LaboratoriesNational Drug Code (NDC):00004-0098Inactive Ingredients:
Important information klonopin 2 mg
You should not use klonopin 2 mg if you have narrow-angle glaucoma, severe liver disease, or if you are allergic to Valium or a similar medicine.
Call your doctor if you have any new or worsening symptoms of depression, unusual changes in behavior, or thoughts about suicide or hurting yourself.
Do not drink alcohol while taking this medicine. Clonazepam may be habit-forming. Never share Klonopin with another person. Keep the medication in a place where others cannot get to it. Selling or giving away this medicine is against the law.
Using Klonopin with opiate medications can result in sedation, respiratory depression, coma, and death.
Before taking this medicine
You should not take Klonopin if you have:
- narrow-angle glaucoma;
- severe liver disease; or
- a history of allergic reaction to any benzodiazepine, such as diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), chlordiazepoxide, flurazepam, and others.
To make sure Klonopin is safe for you, tell your doctor if you have ever had:
- kidney or liver disease;
- asthma, emphysema, bronchitis, chronic obstructive pulmonary disorder (COPD), or other breathing problems;
- porphyria (a genetic enzyme disorder that causes symptoms affecting the skin or nervous system);
- depression or suicidal thoughts or behavior;
- mental illness, psychosis, or addiction to drugs or alcohol; or
- use other medications that cause sedation; or
- if you use a narcotic (opioid) medication.
Some people have thoughts about suicide when taking Klonopin. Your doctor should check your progress at regular visits. Your family or other caregivers should also be alert to changes in your mood or symptoms.
Klonopin is used to treat certain
seizure disorders(including absence seizures or Lennox-Gastaut syndrome) in adults and children.
Klonopin is also used to treat panic disorder(including agoraphobia) in adults.
Klonopin may also be used for purposes not listed in this medication guide.
Pharmacokinetics: Clonazepam is rapidly and completely absorbed after oral
administration. The absolute bioavailability of clonazepam is about 90%. Maximum plasma concentrations of clonazepam are reached within 1 to 4 hours after oral administration. Clonazepam is approximately 85% bound to plasma proteins. Clonazepam is highly metabolized, with less than 2% unchanged clonazepam being excreted in the urine. Biotransformation occurs mainly by reduction of the 7-nitro group.
DOSAGE AND ADMINISTRATION
Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.
The use of multiple anticonvulsants may result in an increase of CNS depressant adverse effects. This should be considered before adding Klonopin to an existing anticonvulsant regimen.
The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg.
Klonopin is administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring.
There is no clinical trial experience with Klonopin in seizure disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of Klonopin and observed closely.
The initial dose for adults with panic disorder is 0.25 mg bid. An increase to the target dose for most patients of 1 mg/day may be made after 3 days. The recommended dose of 1 mg/day is based on the results from a fixed dose study in which the optimal effect was seen at 1 mg/day. Higher doses of 2, 3 and 4 mg/day in that study were less effective than the 1 mg/day dose and were associated with more adverse effects.
Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. To reduce the inconvenience ofsomnolence, administration of one dose at bedtime may be desirable.
Treatment should be discontinued gradually, with a decrease of 0.125 mg bid every 3 days, until the drug is completely withdrawn.
There is no body of evidence available to answer the question of how long the patient treated with clonazepam should remain on it. Therefore, the physician who elects to use klonopin 2 mg for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
There is no clinical trial experience with klonopin 2 mg in panic disorder patients under 18 years of age.
There is no clinical trial experience with Klonopin in panic disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of klonopin 2 mg and observed closely.